Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Platinum Equity Advisors LLC
Mandate

Vinge has advised Platinum Equity Advisors LLC

October 22, 2021 Employment and Benefits Banking and Finance Corporate Commercial Public Procurement M&A

Vinge has advised Platinum Equity Advisors LLC in connection with the acquisition of the global environmental management company Urbaser S.A. and its Swedish subsidiaries Urbaser AB and Nordren AB for an enterprise value of approximately USD 4.2 billion.

Urbaser provides services to more than 70 million people across 25 countries.

Vinge's team primarily consisted of partner Christina Kokko, counsel Ulrich Ziche and associates Christa Anttila (M&A), Gustav Persson (M&A), Fredrika Hjelmberg (Corporate Commercial), Kristoffer Sällfors (Public Procurement), Karl-Gustaw Tobola (Banking and Finance) and Elin Broman (Employment) as well as Sara Dahlros Sköld (VDR Assistant).

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024